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Abstract 
Purpose: The purpose of this study is to describe implementation of comprehensive medication management (CMM) services in a 
gastroenterology (GI) clinic for HCV patients on direct acting antivirals (DAAs), and to evaluate services in terms of identification of 
medication related problems (MRPs), patient satisfaction, and provider satisfaction. Methods: Six months of visit data was 
retrospectively collected to determine demographic data and to analyze pharmacist’s identification of MRPs. Patient satisfaction 
surveys were collected using a thirteen question validated pharmacist-satisfaction survey. After pilot completion, a twelve-question 
survey was sent to all GI clinic staff members to evaluate overall staff satisfaction with services. Results: Ninety-four CMM visits were 
completed. A total of 246 MRPs were identified with an average of 2.6 MRPs per visit. Seventy-eight MRPs were related to appropriate 
indication, 27 to efficacy, 30 to safety, and 109 to adherence. Forty MRPs were related to drug-drug interactions. Patient satisfaction 
surveys revealed that 86% of respondents rated the quality of care and services from the clinical pharmacist as "Excellent". Patients 
better understood and felt confident with therapy. All staff satisfaction survey respondents strongly agreed or agreed that the 
pharmacist made valuable contributions to the clinic and patient care. All also strongly agreed that pharmacy’s CMM services were an 
essential component to the management of HCV. Conclusion: Data supports continued involvement of clinical pharmacists within the 
clinic to promote safety and efficacy of DAAs. Patient and staff satisfaction survey results further illustrate the importance and value 
that CMM provided by clinical pharmacists can provide.  
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Introduction 
Chronic hepatitis C viral (HCV) infection affects approximately 
2.7-3.9 million persons in the United States, and 130-150 
million worldwide.1,2 Chronic infection substantially increases 
the risk of liver cirrhosis and hepatocellular carcinoma, resulting 
in significant morbidity and mortality. Until recently, HCV 
treatment options were limited and relied heavily on marginally 
effective and poorly tolerated agents. Since 2011, the 
treatment of HCV has changed dramatically with the approval 
of new direct antiviral agents (DAAs). DAA regimens, which 
include agents such as simeprevir, sofosbuvir, daclatasvir, and 
ledipasvir, have much higher success rates and are better 
tolerated than previous pharmacotherapy regimens. Many 
have been shown to cure approximately 90% of people with 
chronic infection dependent on the degree of hepatic disease 
and HCV viral load.2 Although these agents demonstrate many 
favorable properties, they still present clinical challenges, 
including many difficult to manage drug-drug interactions and 
a need for strict medication adherence.  
 
Ambulatory clinical pharmacists are well suited to serve the 
HCV population by providing preventative care, comprehensive 
medication management (CMM), disease state evaluations,  
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patient education, adherence support, adverse event 
management, dosing and treatment recommendations, and 
assessment of treatment efficacy.3 Clinical pharmacists can also 
help reduce costs related to adverse events and drug 
interactions associated with therapy. Adherence support 
during treatment may offset costs associated with therapy 
failure and advancing liver disease.3 Additionally, the Infectious 
Diseases Society of America (IDSA) HCV Guidelines recommend 
an assessment for potential drug-drug interactions and patient 
education prior to starting therapy, which further supports the 
inclusion of clinical pharmacy services.4 Despite these benefits, 
few HCV clinics include clinical pharmacists in their workflow. 
Pharmacy services may be difficult to justify financially because 
there is little evidence demonstrating their impact on the 
management of HCV patients.  
 
The purpose of this pilot study is to describe the 
implementation of CMM services in a gastroenterology (GI) 
clinic for HCV patients and to evaluate these services in terms 
of the identification of medication related problems, patient 
satisfaction, and provider satisfaction. 
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Methods  
Setting 
Hennepin Healthcare System, Inc. is a large, urban, safety net 
health-system in Minneapolis, Minnesota, and includes 
Hennepin County Medical Center (HCMC) and primary care 
clinics across the metropolitan area.  Pharmacists are well 
integrated within the health-system and have established CMM 
practices in primary and specialty care clinics throughout the 
institution. Clinical pharmacists provide CMM services as 
outlined by the Patient-Centered Medical Home Model5 to 
ensure that all drug therapy is indicated, effective, safe, and 
convenient. Patients with HCV are managed by specialized 
advanced practice providers and physicians at the GI clinic. 
Providers in this clinic requested a clinical pharmacist to provide 
CMM to HCV patients because they had concerns that patients 
were having MRPs related to drug-drug interactions and 
adherence concerns.   
 
Service Design and Implementation  
Pharmacist services were incorporated into the workflow of the 
clinic (Figure 1) to provide services 8 hours per week.  Providers 
used the EMR to place a referral for a CMM visit, and a 
scheduler contacted the patient to schedule the CMM visit.  
During the CMM visit, the pharmacist conducted a 
comprehensive medication review, reviewing each medication 
for indication, efficacy, safety, and assessing medication 
adherence. Social history was reviewed to assess readiness and 
ability to adhere to therapy and to identify any potential 
adherence barriers. Tools to aid with adherence, such as 
pillboxes, were often given to patients. The pharmacist 
screened the proposed HCV regimen for drug-drug interactions 
and ensured it was appropriate based on guideline 
recommendations and patient-specific factors. The pharmacist 
educated the patient on the proposed HCV therapy focusing on 
pertinent side effects, dosing, what to do if a dose is missed, 
and what to do in the event of a hospitalization. Follow up visits 
were provided to patients who had adherence issues or 
patients whose DAA regimen changed.    The pharmacist 
documented the CMM visit in the EMR, and included a 
classification of MRPs identified related to indication, efficacy, 
safety, and/or adherence.6 The pharmacist electronically sent 
the note and recommendations to the referring provider.  
Recommendations were also discussed with providers in 
person and during monthly care coordination meetings. 
Pharmacists billed for services utilizing medication therapy 
management CPT codes including: 99605 (new patient), 99606 
(established patient), and 99607 (additional units of time). The 
level of service was determined utilizing the Minnesota 
Department of Human Services billing algorithm.7 
 
Clinical pharmacy services in this pilot study were evaluated 
three ways.  Clinical activity was evaluated by a retrospective 
chart review, while patient and clinic staff satisfaction was 
evaluated with surveys.  All data was analyzed using descriptive 
statistics.  This study was exempt from review by the 
Minneapolis Medical Research Foundation Institutional Review 
Board. 
 
Evaluation of Clinical Activity 
To evaluate clinical services provided by pharmacists, data was 
collected retrospectively over a six month time period from 
August 2015 to February 2016.  Variables collected from the 
EMR included age, gender, HCV genotype, HCV polymerase 
chain reaction (PCR), DAA regimen, community pharmacy 
utilized, number and type of medication-related problems 
(MRPs), and the duration of each CMM encounter. The 
community pharmacy the patient used to obtain HCV therapy 
was collected to measure how frequently patients used non-
HCMC pharmacies.     
 
Patient Satisfaction Surveys 
Patient satisfaction surveys were mailed to all patients seen by 
pharmacists from August 2015 through September 2015 and 
from November 2015 through December 2015. Surveys were 
sent during those time frames based on a schedule set forth by 
the pharmacy department.  The pharmacy department typically 
surveys patients receiving pharmacy services twice per year. 
The ten question validated survey includes three domains: 
medication related needs, pharmacist-patient engagement, 
and overall satisfaction.8 Questions were asked using four point 
categorical and Likert scales.   
 
Staff Satisfaction Surveys  
Ten months after ambulatory care pharmacy services were 
implemented in the GI clinic, a survey was sent to all GI clinic 
staff members via Survey Monkey (Palo Alto, CA). The objective 
of the survey was to evaluate provider satisfaction with clinical 
pharmacy services.  The survey consisted of twelve questions 
and used Likert scale and open-ended questions.  The last 
question was open-ended and asked for general comments and 
suggestions to improve the service. 
 
Results  
Clinical Activity  
During the six-month pilot period, 135 CMM referrals were 
made for HCV patients in the GI clinic. Ninety-six CMM visits 
were completed and included 86 new patient visits and 10 
follow up visits. The remainder of the referrals were either 
unable to be completed (29) or were performed in a different 
clinic (12). The average age for patients was 51 years and 70% 
were male (Table 1). The most common HCV genotype 
addressed was genotype 1a (58.1%), and the most commonly 
prescribed medication was ledipasvir/sofosbuvir for 12 weeks 
(48.8%) (Table 2). Over half (65%) of patients obtained their 
HCV medication from HCMC pharmacies.  
 
A total of 246 MRPs were identified from the 96 CMM visits. 
Seventy-eight MRPs (31.7%) were related to appropriate 
indication, 27 (11.0%) to medication efficacy, 30 (12.2%) to 
safety, and 109 (44.3%) to medication adherence. Many of the 
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MRPs related to adherence resulted from patients not 
understanding medication instructions. Of all MRPs identified, 
40 (16.2%) were related to drug-drug interactions with DAA 
treatment. The most common interaction identified included 
use of acid-suppression therapy, such as proton pump 
inhibitors, histamine-2 antagonists, or calcium carbonate.  Drug 
interactions specifically related to acid-suppression therapy 
occurred in 26 of the 40 cases (65%). For a portion of patients 
on acid-suppressing medications, an antacid therapy change 
was required (medicine, dose, etc.).  For other patients, 
education on appropriate timing (between the DAA and acid-
suppressing medication) resolved this interaction.  The average 
visit length was 40 minutes, and the pharmacist identified an 
average of 2.6 MRPs per visit.  
 
Patient Satisfaction  
Forty-five surveys were mailed to patients and fourteen (31%) 
were completed. A majority (57%) of respondents were male 
and between the ages of 41 and 60. Eighty-six percent of 
respondents rated the quality of care and services from the 
clinical pharmacist as "Excellent", 7% responded as "Very 
Good", and 7% responded as "Good". Ninety-three percent of 
respondents strongly agreed or agreed that the pharmacist 
helped them understand the indications of their medications 
and increased their confidence in managing their medications. 
Ninety-three percent of respondents strongly agreed or agreed 
that they would recommend their clinical pharmacist to a friend 
or family member. One patient was not satisfied with their 
clinical pharmacist experience.  
 
Staff Satisfaction 
Electronic surveys were administered to 15 GI clinic staff 
members including nurses, physicians, and support staff. Nine 
surveys were completed, and respondents included registered 
and licensed practical nurses (5), advanced practice provider 
(1), administrative and support staff (3).  All respondents 
strongly agreed or agreed that the pharmacist made valuable 
contributions to the GI clinic and patient care. All respondents 
strongly agreed that pharmacy’s CMM services were an 
essential component to the management of HCV.  When asked 
what additional services pharmacists could provide in the GI 
clinic, respondents reported that the pharmacist should follow 
complicated patients, such as those with cirrhosis, more 
closely.  Respondents reported that the pharmacist was 
valuable in managing drug-drug interactions and requested the 
pharmacist staff GI clinic more frequently than 8 hours per 
week. 
 
Discussion 
Over a six-month period of service design and implementation, 
clinical pharmacy services were successfully implemented. 
Clinical pharmacists were able to identify an average of 2.6 
MRPs per visit. Many of the MRPs identified related to drug-
drug interactions that had potential to impact safety and 
effectiveness of HCV treatment.  The majority of MRPs 
identified related to adherence, which led to the pharmacist 
providing adherence coaching.  Adherence to HCV therapies is 
especially important because incomplete treatment may result 
in treatment failure and could impact drug resistance.3 This 
pilot study suggests that a pharmacist providing CMM can 
contribute to the safe and effective use of DAAs and support 
patients in adhering to treatment.   
 
Clinical pharmacy services were viewed positively by patients 
and GI clinic staff.  Survey results indicated nearly all patients 
felt more confident in managing their medications after 
receiving CMM.  We believe this is due to the focused drug 
counseling and the length of time spent evaluating every 
medication. GI clinic staff reported that CMM services were an 
essential component of the care provided in the GI clinic. Data 
from the survey reflected clinic trends, as referrals remained 
steady throughout the pilot. Additionally, three write-in survey 
comments from a prescribing provider and two registered 
nurses, directly referred to the clinical pharmacist’s expertise in 
the management of drug-drug interactions, which relates to the 
IDSA’s recommendation for evaluation of drug-drug 
interactions.4 Overall, survey data confirms the value of clinical 
pharmacy services to both patients and clinic staff members.  
 
A challenge of implementing CMM services is financial 
justification.  In this pilot study, pharmacists billed insurance 
companies for CMM using MTM CPT codes. Although many 
insurance companies did reimburse CMM services, the lack of 
provider status with Medicare programs limited our overall 
billing power and actual reimbursement did not cover the cost 
of pharmacist services. Future financial justification could 
include revenue generated from patients using health-system 
pharmacies to obtain HCV medications. Financial justification 
could also include considering those costs avoided from 
inappropriate use of DAAs.  For example, if a drug-drug 
interaction were not managed appropriately, a treatment 
failure could result.  
 
This study has limitations.  It is uncertain how CMM impacted 
sustained virologic response (SVR) because of the short 
duration of this study. In this pilot, most patients were seen 
only once by a pharmacist so it is unknown how closer follow-
up might affect outcomes.  Future research should evaluate the 
impact of CMM on SVR and consider the intensity of pharmacist 
follow up provided.  Lastly, response rates of patient and 
provider surveys were low so it is uncertain how representative 
data is of the populations surveyed.   
 
Conclusion 
CMM services provided to HCV patients in a GI clinic strongly 
align with recommendations set forth by the IDSA HCV 
guidelines6, and contribute to safe and effective medication 
use. Our pilot study data supports continued involvement of 
clinical pharmacists within the clinic. Patient and staff 
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satisfaction survey results further illustrate the importance and 
value that CMM provided by clinical pharmacists can provide. 
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Figure 1:  Pharmacist workflow process in GI clinic 
 
CMM: comprehensive medication management 
DAA: direct-acting antiviral 
MRP: medication-related problem 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PharmD CMM follow up if applicable
Patient begins treatment
Patient picks up prescription from Specialty Pharmacy
RN and prior authorization team begins prior authorization process
MRPs are addressed
PharmD visits with patient and forwards recommendations to GI provider and PCP. 
HCV patient identified for DAA treatment and referred to PharmD for CMM 
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Table 1. Demographics of HCV Patients 
 
Age (yrs) (average) 51+/- 7.6 
Gender 
Male (n, %) 
 
60 (70) 
Genotype (n, %) 
 
1a  50 (58.1) 
1b  15 (17.4) 
2  6 (6.9) 
3  8 (9.3) 
4  6 (6.9) 
5  0 (0) 
6  1 (1.1) 
Presence of Cirrhosis (n, %) 18 (20.9) 
HCV= hepatitis C virus 
 
 
 
Table 2.  HCV treatment regimens among patients receiving medication therapy management (n, %) 
 
Ledipasvir/Sofosbuvir (Harvoni) x 12 weeks 42 (48.8) 
Ledipasvir/Sofosbuvir (Harvoni) x 8 weeks 18 (20.9) 
Ledipasvir/Sofosbuvir (Harvoni) + Ribavirin x 12 weeks 2 (2.3) 
Simeprevir + Sofosbuvir + Ribavirin x 24 weeks 1 (1.2) 
Sofosbuvir + Daclatasvir x 12 weeks 6 (7.0) 
Sofosbuvir + Daclatasvir + Ribavirin x 16 weeks 1 (1.2) 
Sofosbuvir + Daclatasvir + Ribavirin x 24 weeks 1 (1.2) 
Sofosbuvir + Ribavirin x 12 weeks 5 (5.8) 
Sofosbuvir + Ribavirin x 16 weeks 1 (1.2) 
Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir (Viekira Pak) x 12 weeks 3 (3.5) 
Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir (Viekira Pak) +  Ribavirin x 12 weeks 6 (7.0) 
HCV=hepatitis C virus 
 
